KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
A phase 2 trial of Imatinib in metastatic cancer, run by Kumquat Biosciences Inc., now recruiting.
Overview
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) is a phase 2 interventional study registered as NCT07406633 by Kumquat Biosciences Inc., with 46 participants planned, started 2026-06-23 and due to reach its primary completion in 2027-10. Interventions recorded: KQB198, Imatinib (Gleevec). Conditions listed: GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour. No results are recorded here; the registry entry is the source.
Setting
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
Phase
Phase 2
Sponsor
Kumquat Biosciences Inc.
Registry
Enrolled
46